Interleukin-1 alpha and Interleukin-1 beta (IL-1α and IL-1β)

Interleukin‑1 alpha and Interleukin‑1 beta are closely related pro-inflammatory cytokines that play central roles in the regulation of immune responses, particularly in mediating inflammation, fever, and the acute-phase response. Both are produced primarily by activated macrophages but can be expressed by a variety of cell types. They exert their effects by binding to specific interleukin‑1 receptors on target cells, triggering intracellular signaling cascades that result in the expression of inflammatory genes[3][6]. IL‑1α is unique among cytokines because both its precursor and mature forms are biologically active; it can act intracellularly via a nuclear localization signal or as a membrane-bound molecule on the cell surface[3]. Its activity is regulated by natural inhibitors such as interleukin 1 receptor antagonist (IL‑1Ra) and soluble forms of its receptor[1]. IL‑1β is synthesized as an inactive precursor that requires cleavage by caspase 1 for activation. It plays key roles in neuroinflammation—being implicated in diseases such as multiple sclerosis models—and has been found at elevated levels in Alzheimer’s disease brain tissue[4]. Both isoforms synergize with other cytokines like TNF-alpha to amplify inflammatory responses. Therapeutic targeting of IL‑1 signaling—such as with anakinra—is used clinically for autoinflammatory conditions but carries risks associated with dampening host defense against infections. Both molecules belong to the broader family of interleukins involved in immune system regulation and are considered validated therapeutic targets for modulating inflammation-driven diseases[6].

Other names

Leukocytic pyrogenLeukocytic endogenous mediatorMononuclear cell factorLymphocyte activating factor

Competitive inhibition of IL‑1 binding to its receptor (for antagonists like anakinra)